Exclusive Summary

• • Favorable competitive landscape: Only one competing compound (NVL-655) in clinical development, positioning our compound as the first in China and second globally.
• • Superior In vitro Activity: Demonstrates stronger activity compare with NVL-655 (including wild-type, single-mutant and double-mutant forms).
• • Enhanced In vivo Efficacy: In murine double-mutant efficacy models, our compound outperforms NVL-655.
• • Strong Brain Penetration- In orthotopic brain tumor models, our compound shows superior efficacy compared to NVL-655